Immunotherapy for gastrointestinal malignancies
PG Toomey, NA Vohra, T Ghansah… - Cancer …, 2013 - journals.sagepub.com
Background Gastrointestinal (GI) cancers are the most common human tumors encountered
worldwide. The majority of GI cancers are unresectable at the time of diagnosis, and in the …
worldwide. The majority of GI cancers are unresectable at the time of diagnosis, and in the …
Targeting the human EGFR family in esophagogastric cancer
A Okines, D Cunningham, I Chau - Nature reviews Clinical oncology, 2011 - nature.com
Esophagogastric cancer represents a significant global health problem, with most patients
presenting with advanced-stage disease and consequently with a poor prognosis …
presenting with advanced-stage disease and consequently with a poor prognosis …
[HTML][HTML] Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized …
T Ruhstaller, P Thuss-Patience, S Hayoz, S Schacher… - Annals of oncology, 2018 - Elsevier
Background This open-label, phase III trial compared chemoradiation followed by surgery
with or without neoadjuvant and adjuvant cetuximab in patients with resectable esophageal …
with or without neoadjuvant and adjuvant cetuximab in patients with resectable esophageal …
[HTML][HTML] Gastric cancer and the epoch of immunotherapy approaches
E Niccolai, A Taddei, D Prisco… - World Journal of …, 2015 - ncbi.nlm.nih.gov
The incidence of gastric cancer (GC) fell dramatically over the last 50 years, but according to
IARC-Globocan 2008, it is the third most frequent cause of cancer-related deaths with a case …
IARC-Globocan 2008, it is the third most frequent cause of cancer-related deaths with a case …
[HTML][HTML] Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy+/− cetuximab in oesophageal cancer
T Crosby, CN Hurt, S Falk, S Gollins, J Staffurth… - British journal of …, 2017 - nature.com
Background: The SCOPE-1 study tested the role of adding cetuximab to conventional
definitive chemoradiotherapy (dCRT), and demonstrated greater toxicity and worse survival …
definitive chemoradiotherapy (dCRT), and demonstrated greater toxicity and worse survival …
Outcomes in the management of esophageal cancer
S Paul, N Altorki - Journal of surgical oncology, 2014 - Wiley Online Library
Esophageal cancer rates have continued to rise in the Western World. Esophageal cancer
will be responsible for an estimated 15,450 deaths in the United States in 2014 alone …
will be responsible for an estimated 15,450 deaths in the United States in 2014 alone …
[HTML][HTML] Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER …
E Deutsch, C Lemanski, JP Pignon, A Levy… - Annals of oncology, 2013 - Elsevier
Abstract Background The ACCORD 16 phase II trial aimed to evaluate the objective
response rate after combination of conventional chemoradiotherapy (CRT) and cetuximab in …
response rate after combination of conventional chemoradiotherapy (CRT) and cetuximab in …
LINE-1 Hypomethylation, DNA Copy Number Alterations, and CDK6 Amplification in Esophageal Squamous Cell Carcinoma
Y Baba, M Watanabe, A Murata, H Shigaki… - Clinical Cancer …, 2014 - AACR
Purpose: Global DNA hypomethylation plays a crucial role in genomic instability and
carcinogenesis. DNA methylation of the long interspersed nucleotide element-1, L1 (LINE-1) …
carcinogenesis. DNA methylation of the long interspersed nucleotide element-1, L1 (LINE-1) …
EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection
The epidermal growth factor receptor (EGFR) plays an important role in tumor progression
and treatment resistance for many types of malignancies including head and neck …
and treatment resistance for many types of malignancies including head and neck …
[HTML][HTML] Recent progress in the neoadjuvant treatment strategy for locally advanced esophageal cancer
S Hou, Z Pan, X Hao, Q Hang, Y Ding - Cancers, 2021 - mdpi.com
Simple Summary Neoadjuvant therapy is recommended as standard care for patients with
locally advanced resectable esophageal cancer. Neoadjuvant chemotherapy (nCT) and …
locally advanced resectable esophageal cancer. Neoadjuvant chemotherapy (nCT) and …